Inpharma

Death risk higher with conventional than with atypical antipsychotics
pp. 2-2(1)

Statins: pleitropic effects of any benefit in CAD?
pp. 3-3(1)

Fatal sepsis with mifepristone, but no need to abort the drug
pp. 3-3(1)

Prevention: a step forward in combating HIV infection
pp. 3-3(1)

Moxifloxacin, nonstandardised antibacterials equivalent in CAP
pp. 4-4(1)

Creativity inappropriate in approval process for antineoplastics
pp. 4-4(1)

Zoledronic acid bones up for breast cancer in Germany
pp. 4-4(1)

Drug-eluting stents from a European perspective
pp. 5-6(2)

Long-acting risperidone cost saving in schizophrenia
pp. 6-6(1)

Enalapril cost saving in patients with HF
pp. 7-7(1)

Aggressive treatment of heart failure decreases costs and hospitalisation
pp. 7-7(1)

Metal on metal hip resurfacing "extremely cost-effective"
pp. 7-7(1)

Antitumour activity is observed with benzylguanine plus temozolomide in children with refractory solid tumours
pp. 8-8(1)

Sertraline is effective in the long-term treatment of night eating syndrome
pp. 8-8(1)

Phenserine may be effective in patients with mild-to-moderate Alzheimer's disease
pp. 8-8(1)

Ofatumumab [HuMax-CD20] is providing encouraging results in the treatment of patients with non-Hodgkin's lymphoma
pp. 8-8(1)

Experimental MC 1 effective after coronary bypass
pp. 8-8(1)

Paclitaxel poliglumex a stellar performer in NSCLC
pp. 9-10(2)

C. difficile evades fluoroquinolones, cephalosporins and rampages
pp. 11-11(1)

Quetiapine makes good sense in bipolar I disorder
pp. 11-11(1)

Orlistat + controlled diet effective for weight loss
pp. 11-11(1)

Artemisinin resistance may be due to S769N PfATPase mutation
pp. 12-12(1)

Higher dose chemo means higher survival rates in breast cancer
pp. 12-12(1)

Bicalutamide beneficial in locally-advanced prostate cancer
pp. 12-12(1)

Twice daily azithromycin [AzaSite] is as effective as tobramycin four times daily in the treatment of bacterial conjunctivitis
pp. 12-12(1)

Quetiapine goes boldly on in bipolar depression
pp. 13-14(2)

Antiretrovirals effective in Haiti: hope for the developing world
pp. 14-14(1)

Perindopril/indapamide superior to enalapril in hypertension
pp. 14-14(1)

An effective sotalol dosing regimen for children
pp. 15-15(1)

US-based researchers report that concomitant clotrimazole substantially increases the relative oral bioavailability of tacrolimus in renal transplant recipients
pp. 15-15(1)

Higher terbinafine dose required in young children
pp. 15-15(1)

CYP2D6 genotype affects metoprolol concentrations
pp. 15-15(1)

Severe toxicity with combined pre-op radiotherapy + chemo
pp. 16-16(1)

Aranesp/Epogen/Procrit: US labels updated with PRCA
pp. 16-16(1)

US NovoSeven labelling update includes new AEs and warnings
pp. 16-16(1)

High renal impairment rate with zoledronic acid in cancer patients
pp. 17-17(1)

US NeutroSpec labelling under review after serious ADR reports
pp. 17-17(1)

Inex Pharmaceutical Corporation has received a notice of noncompliance for liposomal vincristine
pp. 17-17(1)

A once-daily preparation of metformin [Glumetza; Biovail Corporation, Depomed] has been launched in Canada
pp. 17-17(1)

Dong-A Pharmaceutical has received approval from the Korean Food and Drug Administration to market udenafil [Zydena] for erectile dysfunction
pp. 17-17(1)

Ranbaxy Laboratories introduced two first-line HAART products, Virolis-E and Virocomb-E, in India
pp. 17-17(1)

EU regulatory news
pp. 18-18(1)

Other US regulatory news
pp. 18-18(1)

US product approvals
pp. 18-18(1)

Product Introductions
pp. 19-19(1)